Guidance| Page 3 of 4 | The British Society of Gastroenterology

Guidance

Test and treat for Helicobacter pylori (HP) in Dyspepsia

First published on 01 Oct 2016

Helicobacter pylori in dyspepsia: test and treat – consultation and guidance documents from Public Health England. Guidance for primary care/ CCGs published October 2016. This guidance has been endorsed by members of the BSG Gastroduodenal Section. https://www.gov.uk/government/publications/helicobacter-pylori-diagnosis-and-treatment

Guidance

Treatment Recommendations for the management of patients with chronic HCV Infection

First published on 01 Feb 2016

These recommendations were developed at a consensus meeting of clinicians and interested parties on 5 January 2016. Therapies that are NICE approved are presented in bold and those that are NICE unapproved are italicised. The prices of the different regimens […]

Guidance

BSG Guidance on the Use of Biosimilar Infliximab CT-P13 in IBD

First published on 01 Feb 2016

February 2016 Introduction: Dr AB Hawthorne, Chair BSG IBD Section Committee The infliximab biosimilar CT-P13 (Remsima or Inflectra) received marketing authorisation in June 2013.The drug is now widely used in the treatment of inflammatory bowel disease. There is sufficient data […]

Guidance

NICE guidance on Daclatasvir for treating chronic hepatitis C

First published on 25 Nov 2015

NICE technology appraisal guidance [TA364] Published date: November 2015

Guidance

NICE guidance on Ledipasvir–Sofosbuvir for treating chronic hepatitis C

First published on 25 Nov 2015

Guidance

UK Key Performance Indicators and Quality Assurance Standards for Colonoscopy

First published on 27 Oct 2015

Rees CJ, Thomas-Gibson S, Rutter MD, Baragwanath P, Pullan R, Feeney M, Haslam N. Colonoscopy is the ‘gold standard’ investigation for assessment of the large bowel allowing diagnosis, biopsying, and therapy to be undertaken. Colonoscopy detects and prevents colorectal cancer, […]

Guidance

NICE guidance on Ombitasvir–Paritaprevir–Ritonavir with or without Dasabuvir for treating chronic hepatitis C

First published on 25 Oct 2015

NICE technology appraisal guidance [TA365] Published date: November 2015

Guidance

NHS England service specification for Operational Delivery Networks for hepatitis C care in adults

First published on 22 Oct 2015

22nd October 2015 NHS England has published the service specification for Operational Delivery Networks (ODNs) for hepatitis C care in adults. The full document is available below. Many BSG members will have been involved in the set up processes to date […]

Guidance

Vedolizumab for the treatment of adult patients with moderately to severely active Crohn’s disease

First published on 26 Aug 2015

Vedolizumab (Entyvio) is recommended. It is a possible option for adults with moderate to severe Crohn’s disease if a tumour necrosis factor (TNF)-alpha inhibitor isn’t suitable or hasn’t worked well enough. People should be able to have vedolizumab until it […]

Guidance

NICE guidance on Naloxegol for treating opioid-induced constipation

First published on 22 Jul 2015

Naloxegol is recommended, within its marketing authorisation, as an option for treating opioid induced constipation in adults whose constipation has not adequately responded to laxatives. An inadequate response is defined as opioid-induced constipation symptoms of at least moderate severity in […]